Medical Advocates

Pegylated Interferons
    Hepatitis C

Peg Interferon Alfa 2a
Peg Interferon Alfa 2b

General Reports
Safety
Viral Dynamics
Efficacy Studies
Adverse Events
Quality of Life
Adherence
 

 

Peg Interferons Main Page Main New/Newsworthy  Home Page

Last Update:  April 10, 2017
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
     

     Journal Papers, Abstracts, and Commentaries
 
 
Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
Liu TW, Tsai PC, Huang CI,  et al
J Formos Med Assoc
. 2017 Apr 4
Abstract

Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
Mak SK, Sin HK, Lo KY,
Clin Exp Nephrol. 2017 Jan 12.

Abstract

A nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.
Wei L, Li J, Yang X, Wang G, et al
J Gastroenterol Hepatol
. 2016 Apr 4.
Abstract

FULL-TEXT ARTICLE
Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study.
Ide K, Kawasaki Y, Yamada H, Masaki N.
Drug Des Devel Ther
. 2016 Mar 22;10:1217-23.
Paper

FULL-TEXT ARTICLE
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Kovari H, Russmann S, Ledergerber B, et al  
PLoS One
. 2015 Jul 28;10(7):e0133879.
Paper

Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
Devaki P, Jencks D, Yee BE, Nguyen MH.
Hepatol Int. 2015 May 28.

Abstract

Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma-A retrospective multicenter study.
Harada N, Hiramatsu N, Oze T,  et al
J Med Virol
. 2015 Mar 13.
Abstract

Effect of Aging, Glucose Level, and HIV Viral Load on Response to Treatment with Pegylated Interferon Plus Ribavirin in HIV/HCV Co-Infected Women.
Nasta P, Maida I, Cattelan AM, et al
J Womens Health (
Larchmt)
. 2015 Feb;24(2):159-64
Abstract

Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
Ackefors M, Castedal M, Dahlgard O,  et al
Infect Dis (Lond). 2015 Feb 4:1-9.
Abstract

Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
Lin J, Wang W, Xu Y,  et al
J Med Virol
.
2015 Feb 4.
Abstract

Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.
Yee BE, Nguyen NH, Zhang B,  et al
Eur J Gastroenterol Hepatol
. 2014 Aug 28
Abstract

Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?
Serfaty L.
Liver Int. 2014 Feb;34 Suppl 1:11-2. .

Abstract

Characteristics of the cellular immune response in HIV/HCV patients with hemophilia during peginterferon/ribavirin therapy in southern China.
Yingying L, Jiangrong W, Jing L.
Diagn Microbiol Infect Dis
. 2013 Oct 30.
Abstract

Identification of Naďve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin
Andriulli A, Marco VD, Margaglione M,  et al
J Hepatol
. 2013 Aug 20.
Abstract

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
Pearlman BL, Ehleben C.
Hepatology.
2013 Jul 19.
Abstract

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H, Aida Y, Ishiguro H, Yoshizawa K, et al
J Med Virol
. 2013 Jun 17.
Abstract

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
Oze T, Hiramatsu N, Yakushijin T, et al
J Gastroenterol
. 2013 May 21
Abstract

Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area.
Chung HJ, Lee JW, Kim YS, Lee JI.
Intervirology. 2013 Jan 9
Abstract

Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance
treatment.
Neukam K, Mira JA, Gilabert I,  et al
Eur J Clin Microbiol
Infect Dis
. 2011 Oct 6
Abstract

Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4+ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients.
Reiberger T, Payer BA, Kosi L,  et al
J Infect Dis
. 2011 Jun;203(12):1802-1806.
Abstract

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
Roomer R, Hansen BE, Janssen HL, de Knegt RJ.
Hepatology
. 2010 Jul 29
Abstract

Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C.
Z
hao S, Liu E, Wei K, Wang Y, et al
Eur J Clin Microbiol Infect Dis
. 2010 Sep 9.
Abstract

Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response.
Zeuzem S, Poordad F.

Curr Med Res Opin
. 2010 Jul;26(7):1733-43
Abstract

Meta-analysis of factors associated with sustained viral response in patients on
hemodialysis treated with standard or pegylated interferon for hepatitis C infection.
Alavian SM, Tabatabaei SV.
Iran J Kidney Dis. 2010 Jul;4(3):181-94.
Abstract

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg-Interferon {alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
Saadoun D, Resche Rigon M, et al
Blood
. 2010 May
Abstract

Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
Levast M, Larrat S, Thelu MA,  et al  
J Med Virol
. 2010 Mar 24;82(5):747-754.
Abstract

Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.
Van den Eynde E, Tiraboschi JM, Tural C, et al
AIDS
. 2010 Mar 17.
Abstract

   

Safety
     

     Journal Papers, Abstracts, and Commentaries

  Safety of peginterferon in the treatment of chronic hepatitis C.
Hashemi N, Rossi S, Navarro VJ, Herrine SK.
Expert Opin Drug Saf. 2008 Nov;7(6):771-81

Abstract

Viral Dynamics
     

Peg Interferons/Ribavirin

     Journal Papers, Abstracts, and Commentaries

 
FULL-TEXT ARTICLE
Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil.
Barcaui HS, Tavares GC, May SB,  et al
PLoS One
. 2013 Jul 9;8(7):e67734.
Paper

Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases.
Akuta N, Suzuki F, Arase Y,  et al 
Intervirology
. 2010 Mar 3;53(3):188-192
Abstract


Diagnostics
     

     Journal Papers, Abstracts, and Commentaries

  Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay
Matsuura K, Tanaka Y, Takagi K,
Rinsho Byori. 2007 Nov;55(11):983-8

Abstract

Efficacy (General Reports)
     

Peg Interferon Miscellaneous Efficacy Studies
 

    Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.
Fujii H, Nishimura T, Umemura A, et al  
World J Hepatol. 2015 Dec 8;7(28):2841-8.
Paper

Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort
Doyle JS, Deterding K, Grebely J, et al
J Viral Hepat
. 2015 Jun 22.

Abstract

Safety and Efficacy of Triple Therapy With Peginterferon, Ribavirin, and Boceprevir Within an Early Access Program in Spanish Patients with Hepatitis C Genotype 1 with Severe Fibrosis: SVRw12 Analysis.
Calleja J, Pascasio J, Antorán BR, et al
Liver Int
. 2014 Aug 11
Abstract

FULL-TEXT ARTICLE
Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors.
Coppola N, Pisaturo M, Sagnelli C, et al
PLoS One
. 2014 Apr 11;9(4):e94542.
Paper

Peg Interferon Monotherapy
 

     Journal Papers, Abstracts, and Commentaries
 
 
Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon {alpha}
Wiegand J, Deterding K, Cornberg M, Wedemeyer H.
 J Antimicrob Chemother.
2008 Sep 5
Abstract 
 

Pegylated interferon treatment of acute pericarditis associated with acute hepatitis C.
Kocaman O, Aygün C, Konduk T, et al
Turk J Gastroenterol. 2007 Dec;18(4):268-271.
Abstract 
 

Peg Interferon/Ribavirin
 
     Journal Papers, Abstracts, and Commentaries
 
  Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.
Miuma S, Ichikawa T, Miyaaki H, ,  et al
|J Interferon Cytokine Res
. 2016 Jun;36(6):358-366
Abstract
 
 
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.
Bagaglio S, Uberti-Foppa C, Di Serio C, et al
Medicine
(Baltimore)
. 2015 Oct;94(43):e1876.
Abstract

Effectiveness of Extending Treatment Duration in Therapy with Pegylated Interferon and Ribavirin for Genotype 2 Hepatitis C Virus Infection.
Nanba S, Ikeda F, Fujioka S, et al
Acta Med Okayama
. 2015 Aug;69(4):237-44.
Abstract.

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
Mira JA, Neukam K, López-Cortés LF,  et al
Eur J Clin Microbiol Infect Di
s
. 2015 Jun 27.
Abstract.

Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response.
Sood A, Midha V, Goyal O.
J Clin Exp Hepatol
.
2015 Mar;5(1):2-7
Abstract.

FULL-TEXT ARTICLE
Retreatment with peginterferon and ribavirin in chronic hepatitis C.
Jo YM, Lee SW, Han SY,  et al
World J Gastroenterol. 2015 Feb 14;21(6):1994-9
Paper

Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: Propensity score-matched analysis.
Yokoyama S, Kawakami Y, Imamura M,  et al
J Gastroenterol Hepatol
. 2014 Aug 5.
Abstract.

OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naďve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Bruno R, Cariti G, Nasta P,  et al
Liver Int
. 2014 Jul 19.
Abstract.

Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy
Nelson RE, Hoop R, Korner E,  et al
Ann Pharmacother
. 2014 Apr 23
Abstract.

Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
Shoeb D, Dearden J, Weatherall A,  et al
J Hepatol. 2013 Nov 26
Abstract

Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection.
Zhou K, Ferguson J, Bau S, Saab S.
J Clin Gastroenterol
. 2013 Sep 16
Abstract

HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin.
Feijoo J, Eirea M, Limeres J,  et al
Oral Dis
. 2013 Apr 12.
Abstract

Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C : A Meta-Analysis.
Flori N, Funakoshi N, Duny Y,et al
Drugs
. 2013 Feb 23.
Abstract

A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
Oze T, Hiramatsu N, Mita E, et al
Hepatol Res
. 2013 Jan;43(1):35-43.
Abstract

Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials.
D'Heygere F, George C, Van Vlierberghe H,  et al
J Med Virol
. 2011 May;83(5):815-9.
Abstract

Extended treatment duration for treatment naďve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated
interferon and ribavirin.
Parikh M, Singh A, Sood G.
J Viral Hepat
. 2010 Oct 18. doi: 10.1111
Abstract
 

FULL-TEXT ARTICLE
Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection.
Singhal A, Jain AB, Burke M, Black M.
Exp Clin Transplant
. 2010 Sep;8(3):214-9.
Paper

Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response.
Fernández-Rodríguez CM, Alonso S, Martinez SM,  et al
Am J Gastroenterol
. 2010 Aug 10
Abstract

Thyroid Function Outcomes Following Pegylated Interferon-alpha and Ribavirin Therapy For Chronic Hepatitis C.
Tran HA, Reeves GE, Ianna EA, Leembruggen N.  
Endocr Pract
. 2010 May 3:1-16
Abstract

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg-Interferon {alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
Saadoun D, Resche Rigon M, et al
Blood
. 2010 May
Abstract

Hepatitis: Treatment of chronic hepatitis C-how much interferon is enough?
Ferenci P.
Nat Rev Gastroenterol Hepatol
. 2010 Apr;7(4):191-3
Abstract
 


Quality of Life
     

     Journal Papers, Abstracts, and Commentaries

  Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
Marcellin F, Protopopescu C, Poizot-Martin I,  et al
Eur J Gastroenterol Hepatol. 2016 May 12
Abstract

Assessment of health-related quality of life predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.
Matsushita H, Ikeda F, Iwasaki Y,  et al
J Gastroenterol Hepatol
. 2013 Jul 22
Abstract

Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.
Nayman Alpat S, Usluer G, Yavuz H

J Chemother. 2008 Feb;20(1):101-5. L

Abstract


Adherence
 

     Journal Papers, Abstracts, and Commentaries

  Hepatitis C patients' self-reported adherence to pegylated interferon and ribavirin.
Weiss JJ, Bhatti L, Dieterich DT, et al

Aliment Pharmacol Ther. 2008 Apr 16

Abstract


Peg Interferons Main Page Main New/Newsworthy  Home Page

Pegylated Interferons
Hepatitis C